The lead candidate in the series is the APP selective small molecule FAH65 and its active enantiomer FAH65(-), which displays potent inhibition of BACE1 in vitro and in vivo, and elicits improvement in memory in an AD mouse model after oral treatment. Here, APP is linked to Alzheimer disease.